ExScientia Ltd

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ExScientia reports robust Q4 earnings, poised for precision medicine growth

ExScientia's Q4 2022 earnings call highlighted strong financial performance, key collaborations, and advancements in pipeline programs. The company's focus on AI-driven precision medicine and solid cash position bode well for future growth. Challenges in program management and cost control exist, but opportunities for innovation and partnerships are abundant.

ExScientia reports 15% revenue growth, poised for precision medicine leadership

ExScientia Ltd delivered strong financial performance with a 15% increase in quarterly revenue and a robust cash position, driven by successful product launches and cost-saving initiatives.
The company's focus on personalized medicine, innovative product development, and strategic financial management positions it well for future growth and market leadership.
While facing challenges in molecule differentiation and cost efficiency, ExScientia has opportunities to leverage biomarkers, advance clinical programs, and expand market presence.

ExScientia advances clinical trials and precision medicine with strong financials

ExScientia's Q2 2023 earnings call showcased progress in clinical trials, precision medicine, and AI integration, supported by a strong financial position.
The company's focus on innovation, cost efficiency, and strategic partnerships positions them well for future growth and advancements in drug discovery.
Challenges lie in managing milestone payments, operational complexities, and staying competitive through biologics investments and partnerships.
Opportunities abound in expanding collaborations, attracting industry interest, and unveiling advancements in biologics for pipeline growth from 2024 onwards.

ExScientia excels in Q3, poised for growth in precision medicine

ExScientia's Q3 performance reflects progress in oncology programs, financial strength, and a focus on precision drug design and partnerships.
The company's strengths lie in its robust cash position, innovative approach to drug design, and operational efficiency influenced by past projects.
Challenges include market adaptability, program prioritization, and maintaining competitiveness, while opportunities exist in advancing the pipeline and leveraging partnerships for growth.

ExScientia reports robust Q4 earnings, eyes growth through innovation

ExScientia's Q4 2023 earnings call showcases strong financial and operational performance.
The company's focus on innovation, partnerships, and efficiency drives growth.
Challenges include competition, innovation sustainability, and quality maintenance.
Opportunities lie in business development, automation, and efficient drug creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Exscientia p.l.c. ("Exscientia" or "the Company") (NASDAQ:EXAI) and certain of its officers.

EXAI SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Exscientia p.l.c. Investors to Join the Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=83112&wire=1 or contact Joseph E. Levi, Esq.

Investors Who Lost Money on Exscientia plc(EXAI) Should Contact Levi & Korsinsky About Pending Class Action - EXAI

NEW YORK , June 6, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exscientia plc ("Exscientia" or the "Company") (NASDAQ: EXAI) and reminds investors of the June 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Exscientia To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 investing in Exscientia stock or options between March 23, 2022, and February 12, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia

LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

The Schall Law Firm Is Urging Investors Who Have Suffered Losses In Exscientia Plc To Reach Out. Please Be Mindful Of The Deadline In This Matter

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development. Appointed to Chief Technology Officer, John P. Overington, Ph.D., will assume strategic leadership over the company's technology solutions to further accelerate Exscientia's AI-led drug design platform an.

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Exscientia p.l.c. ("Exscientia" or "the Company") (NASDAQ:EXAI) and certain of its officers.

EXAI SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Exscientia p.l.c. Investors to Join the Class Action Lawsuit!

SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP  reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Exscientia plc (NASDAQ: EXAI) securities between March 23, 2022 and February 12, 2024. Exscientia in an artificial intelligence (“AI”) driven Pharma-tech company that engages in the design and develop differentiated medicines for diseases with high unmet patient needs.

EXAI STOCKHOLDERS – Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Exscientia plc Class Action

LOS ANGELES , June 5, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

IMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exscientia plc (“Exscientia” or the “Company”) (NASDAQ: EXAI) and reminds investors of the June 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia

LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ:EXAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 23, 2022 and February 12, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

The Schall Law Firm Urges Investors with Losses in Exscientia plc to Reach Out Prior to the June 25th Deadline

LOS ANGELES, June 05, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc (“Exscientia” or “the Company”) (NASDAQ: EXAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 23, 2022 and February 12, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before June 25, 2024.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm

NEW YORK , June 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Shareholders that lost money on Exscientia plc(EXAI) should contact The Gross Law Firm about pending Class Action - EXAI

LOS ANGELES , June 4, 2024 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ: EXAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ:EXAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 23, 2022 and February 12, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

EXAI DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the “Class Period”), of the important June 25, 2024 lead plaintiff deadline.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI

NEW YORK, NY / ACCESSWIRE / June 3, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=82599&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Exscientia plc (EXAI) - June 25, 2024 Deadline to Join – Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ:EXAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 23, 2022 and February 12, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

EXAI IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm

The average of price targets set by Wall Street analysts indicates a potential upside of 57.2% in Exscientia (EXAI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect?

LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ:EXAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 23, 2022 and February 12, 2024, inclusive (the "lass Period"), are encouraged to contact the firm before June 25, 2024.

DEADLINE ACTION UPDATE: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ:EXAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 23, 2022 and February 12, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 31, 2024 / If you suffered a loss on your Exscientia plc (NASDAQ:EXAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/exscientia-plc-lawsuit-submission-form?prid=82422&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Exscientia plc(EXAI)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc ("Exscientia" or "the Company") (NASDAQ:EXAI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 23, 2022 and February 12, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 25, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the Firm

NEW YORK , May 30, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the "Class Period"), of the important June 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Exscientia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAI

Toro

BOSTON--(BUSINESS WIRE)-- #FamilyBusiness--BanyanGlobal Family Business Advisors elects Ben Francois as managing partner, succeeding Rob Lachenauer, co-founder of the firm.

BanyanGlobal Family Business Advisors Elects Ben Francois as New Managing Partner

SACRAMENTO, Calif.--(BUSINESS WIRE)-- #agencyacquisition--Inszone Insurance Services, a leading national provider of commercial, personal, and benefits insurance, is pleased to announce its acquisition of John Henry Insurance Services. Established in 2003 by John Henry Garcia, the agency has built a reputation for reliability and trust over nearly two decades. With a focus on delivering customized insurance solutions and providing unwavering support, John Henry Insurance Services has been a trusted partner for busi.

News for ExScientia Ltd Stock (EXAI)